Multiple People Get Sick After Cannabis Found in Haribo
Several people reported feeling sick in the Netherlands after consuming Haribo fizzy candy that contained traces of cannabis.
A batch of Haribo's Happy Cola F!ZZ was recalled after a family, including children, reported feeling unwell after consuming the product, the Netherlands Food and Consumer Product Safety Authority said.
Drug contamination in candy is not uncommon and can be very dangerous, especially as children are likely to consume it.
A spokesperson for Haribo told Newsweek in an emailed statement that the contaminated items were in a specific product and batch in the Netherlands and did not affect products in other countries.
The German confectionary company added that it is "working closely with the authorities to support their investigation and establish the facts around the contamination."
Several members of a family reported that they had been feeling unwell after consuming the candy and reported it to police, according to Dutch broadcaster SBS6.
A spokesperson for the Netherlands Food and Consumer Product Safety Authority said that samples of the product were taken and cannabis was found in them. The agency said it immediately contacted Haribo and a safety warning was issued.
The contamination affects three 1kg packs of sweets, but a full recall of the product has been undertaken in the Netherlands as a precaution.
The affected batch has an expiration date of January 2026 and the production code L341-4002307906.
Anyone with any candy from the affected batch is asked to send it back to the company, not to the point of purchase.
"How the cannabis ended up in the sweets is still unknown," a spokesperson for the Netherlands Food and Consumer Product Safety Authority told the Dutch news agency ANP. "The police are investigating the matter further."
A spokesperson for Haribo told Newsweek in an emailed statement: "The safety of our consumers is our highest priority and HARIBO takes this incident very seriously, which is why a recall has been issued in the Netherlands. HARIBO is working closely with the authorities to support their investigation and establish the facts around the contamination."
Dutch police spokesperson Chantal Westerhoff: "We want to know exactly how this got into the candy...and how the bags ended up in the store."
A police investigation is ongoing. The Netherlands Forensic Institute is examining the contaminated candy to gather more information.
2025 NEWSWEEK DIGITAL LLC.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
3 hours ago
- Business Wire
Leyden Labs Lands €20 Million EIB Investment Facilitated by HERA to Advance Pandemic Preparedness Activities
LUXEMBOURG & LEIDEN, the Netherlands--(BUSINESS WIRE)--The European Investment Bank (EIB) and Dutch clinical-stage biotechnology company Leyden Laboratories B.V. have signed a €20 million financing deal to advance development of the Company's broadly-protective antibodies to defend against seasonal and pandemic viral infections. Leyden Labs' lead program is a pan-influenza nasal spray currently in clinical development (PanFlu), which has the potential to provide first-in-class influenza protection and meaningfully reduce the burden of influenza infection, including in infection from Avian Flu (H5). The venture debt financing agreement is supported under the European Commission's InvestEU programme and specifically falls under 'HERA Invest.' This €110 million initiative from the European Health Union is meant to address biodefence, pandemic readiness and antimicrobial resistance in Europe, as a top-up to the European Union's InvestEU initiative, funded by the EU4Health programme. 'The COVID-19 pandemic taught us multiple lessons, including that we should strengthen the EU's preparedness and autonomy in key areas like bio sciences,' stated EIB Vice President Robert de Groot. 'With the support of the European Commission, the EIB backs highly innovative EU companies like Leyden Labs with venture debt, enabling them to grow and thrive in Europe. Technological innovations from companies like Leyden Labs are key for European competitiveness and the well-being of our society.' Hadja Lahbib, Commissioner for Equality, Preparedness and Crisis Management, added: 'Respiratory viruses are common and affect us all, especially the most medically vulnerable. Today's agreement reaffirms our commitment to invest in innovation to strengthen preparedness and protection against respiratory viruses. HERA Invest is a prime example of Europe at the forefront of medical advancements in response to serious threats to health.' 'We are thrilled with this endorsement of our approach and support from HERA and the European Investment Bank. This will accelerate our efforts to provide broad, universal protection against current and future viral outbreaks. We are grateful that HERA and the EIB understand the urgency and significance of investing in initiatives to ensure Europe is prepared for pandemic viruses. This concern is greater than ever given the increasing threat of an avian influenza outbreak,' said Koenraad Wiedhaup, co-founder and CEO of Leyden Labs. Leyden Labs' product candidates are nasal sprays that administer broadly protective antibodies directly to the respiratory mucosa. Leyden Lab's solutions are designed to work at the earliest moment, before the virus even reaches systemic circulation. Systemically administered vaccines primarily generate systemic protection against viruses, however, this may be a limitation that contributes to suboptimal efficacy. Airborne viruses, including influenza, do not directly enter systemic circulation, but rather, they enter the body through the nose and mouth. The Company's antibodies aim to protect against full viral families, so they keep working even when a virus mutates and evolves. This intranasal strategy also has the potential to benefit people with weakened immune systems because it does not rely on the person to be able to mount an immune response in order to be protective. The Company's novel approach has the potential to transform the way the healthcare ecosystem thinks about viral prophylaxis, while also providing an innovative solution for use both in times of seasonal outbreaks as well as pandemic emergencies. HERA's responsibility is to ensure that the EU and Member States are ready to act in the face of cross-border health threats. The €20 million proceeds of this financing will support further development of Leyden Labs' novel, non-vaccine approach to fighting respiratory viruses to contribute to European pandemic preparedness efforts. Background Information: Health Emergency Preparedness and Response (HERA). The European Commission's Health Emergency Preparedness and Response Authority (HERA) supports projects that strengthen preparedness and response capacities in the field of health. HERA was established as a direct consequence of the lessons learned from the initial management of the COVID-19 pandemic, to ensure a solid Union response to serious-cross border health threats and secure ready availability and accessibility of medical countermeasures. HERA's responsibility is to ensure that the EU and Member States are ready to act in the face of cross-border health threats, and its mandate covers both the strengthening of preparedness in advance of future emergencies and the implementation of a swift and efficient response once crisis hits. HERA Invest is a €110 million top-up to the InvestEU programme, funded by the EU4Health programme. It is implemented by the EIB and supports projects that focus on pathogens with pandemic potential, chemical, biological, radiological, nuclear threats, and antimicrobial resistance. Together with HERA, the EIB assesses whether an operation meets HERA Invest's criteria. The InvestEU programme provides the European Union with crucial long-term funding by leveraging substantial private and public funds in support of a sustainable recovery. It also helps mobilise private investment for EU policy priorities, such as the European Green Deal and the digital transition. InvestEU brings together under one roof the multitude of EU financial instruments previously available to support investment in the European Union, making funding for investment projects in Europe simpler, more efficient and more flexible. The programme consists of three components: the InvestEU Fund, the InvestEU Advisory Hub and the InvestEU Portal. The InvestEU Fund is deployed through implementing partners who will invest in projects using the EU budget guarantee of €26.2 billion. The entire budget guarantee will back the investment projects of the implementing partners, increase their risk-bearing capacity and thus mobilise at least €372 billion in additional investment. The European Investment Bank (EIB) is the long-term lending institution of the European Union, owned by its Member States. The Netherlands owns a 5,2% share of the EIB. It makes long-term finance available for sound investment in order to contribute towards EU policy goals and national priorities. More than 90% of its activity is in Europe. Over the last ten years, the EIB has made available more than €27 billion in financing for Dutch projects in various sectors, including research & development, sustainable mobility, drinking water, healthcare and SMEs. In 2024 the EIB Group, which also includes the EIB's subsidiary, the European Investment Fund (EIF), made available more than €3 billion for Dutch projects. Leyden Laboratories B.V. (Leyden Labs), founded in 2020, is a clinical-stage biotechnology company based in the Netherlands. Leyden Labs is working to free people from the threat of respiratory viruses, by leveraging its Mucosal Protection Platform to develop a portfolio of candidates aimed at providing protection against influenza, coronaviruses, and other respiratory viruses through a new class of broadly protective nasal sprays. Leyden Labs is supported by a strong syndicate of investors and ambassadors; VC investors include GV (formerly Google Ventures), Casdin Capital, F-Prime Capital, ClavystBio (a life sciences venture investor established by Temasek), Polaris Partners, Qiming Venture Partners, Invus, SoftBank Vision Fund 2, Byers Capital / Brook Byers and Bluebird Ventures. To learn more, visit CR9114, Leyden Labs' lead product candidate for the PanFlu program, is a human monoclonal antibody that protects against influenza in preclinical models. Leyden Labs holds an exclusive license from Janssen Pharmaceuticals Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to develop and commercialize CR9114.
Epoch Times
6 hours ago
- Epoch Times
3 Patients Are Killed in a Fire That Broke out at a Hospital in the German City of Hamburg
BERLIN (AP) — Three older patients were killed and many people were injured in a fire that broke out overnight at a hospital in the German city of Hamburg, authorities said Sunday. Firefighters were alerted to the blaze at the hospital, the Marienkrankenhaus, shortly after midnight. It broke out in a room in the geriatric ward, on the ground floor of the building, and spread to the facade of the floor above. Smoke spread across the building's four floors, German news agency dpa reported.
Yahoo
7 hours ago
- Yahoo
Going Dutch: Morgantown Police Department introduces newest K-9 and handler
Jun. 2—MORGANTOWN — The Morgantown Police Department's newest officer is a bit different than most. He does not carry a badge, does not drive a cruiser, and spends his nights in a kennel—but he does have a drive like no other. Edo, a young Dutch shepherd, is currently undergoing training to become the department's newest dual-purpose K-9, trained in both narcotics detection and patrol work. He is paired with Patrol Officer First Class Marlee France, who is also undergoing training and certification as a first-time K-9 handler with the department. "This has always been something I wanted to do, " said France, a Preston County native and WVU graduate. "I've always admired the K-9s and once I got on the road and saw them working, I knew I wanted to be part of it." The pair are currently in week three of an eight-week process. If all goes to plan, they will be fully operational by mid-summer. "We are learning together and I am realizing a lot of the little things matter the most, " France said. Morgantown's first Dutch shepherd According to Sgt. Brad Palmer, who works with K9s, Edo is the first Dutch shepherd to join the department. The breed, comparable in temperament as well as drive to the Belgian Malinois, is one of three commonly used in law enforcement. German shepherds and Malinois are the others. Morgantown's K-9 unit, once Edo is certified, will be back to four dogs, with the other current working dogs all being German shepherds. Edo was selected from Shallow Creek Kennels, a respected provider of law enforcement dogs, many of which are imported from overseas. Morgantown's team tested several dogs across different breeds before selecting Edo. "The drive he has ... it is just constant, " France said. "He's always ready to work." A working dog Unlike a pet at home, police dogs like Edo are bred and trained for specific tasks, and their lives are built around that work. They are not family pets, even if they are socialized and friendly. "There is no 'off switch' with these dogs, " Palmer said. "When they are not working, they need structured downtime, which is why they are kenneled when off-duty. They are constantly looking for their toy—which means work." Play is a huge part of training, but only as a reward. Edo's favorite toy is a ball, and he only gets access to it when he is working or training. The idea is simple: No play without purpose. "If he just had his ball all day, it would not mean anything anymore, " Palmer explained. "The toy is his paycheck ; he only earns it when he works." France says she sees a clear distinction between Edo and her own two German shepherds at home. "They will play for a while and then relax. He is always on, always looking to work. That's the biggest difference, " she said. "But when I grab my keys or start walking to my car, he gets excited. He knows it is time to go to work." Palmer talks about how rewarding it is when working with k-9s, "it is watching the satisfaction of working dogs." 'A force multiplier' Police K-9s are more than crime-fighting companions—they are a resource that saves time and manpower. "These dogs are a force multiplier, " Deputy Chief Christopher Ruehmer said. "They allow us to do more with less, whether that is detecting narcotics, searching for suspects or performing building searches." Edo is being trained to notify his handler in a passive indication when finding drugs. Despite being trained to work, Edo is very socialized. He has been introduced to children, including France's, and other dogs. Still, officers are careful about where and how the dogs interact outside of work. "They are trained for patrol, " Palmer emphasized. "That means their instincts are different. In a real-world situation, if someone's hiding in a bush and the dog finds them first, there is a risk of a bite. That is why we are selective about deploying them for search and rescue." When possible, such duties are handed off to agencies that use bloodhounds, like the department in Granville. However, in life-threatening situations, such as a missing child, the K-9s will be deployed. Local efforts Edo's training and acquisition were made possible in large part thanks to the West Virginia Law Enforcement Police K-9 Fund, a nonprofit created about eight years ago. Besides others in the community of Morgantown, Palmer has been a big part in this nonprofit. Based in Morgantown, the fund helps departments across West Virginia. Agencies apply for grants with the fund, and many departments in the state have benefited from the support. "They have probably helped us get all of our last several dogs, " Palmer said. "It is a vital resource for agencies that might not otherwise have the budget to fund a K-9 unit." With five weeks of training to go, France and Edo are making great progress. While there is still plenty to learn, they have already developed skills and a bound that is essential for field success. "He has picked up everything so fast, " France said. "We're learning together, and I think we are going to make a really good team."
